4-Adamantyl-(2-(arylidene)hydrazinyl)thiazoles as potential antidiabetic agents : experimental and docking studies
Aim: To develop an efficient and cost-effective antidiabetic agent. Methods: A simple and convenient Hantzsch synthetic strategy was used to prepare 4-adamantyl-(2-(arylidene)hydrazinyl)thiazoles. Results: Fifteen newly established structures of 4-adamantyl-(2-(arylidene)hydrazinyl)thiazoles were tested for their α-amylase, antiglycation and antioxidant activities. Almost all tested compounds showed excellent α-amylase inhibition. Compounds 3a and 3j exhibited the highest potency, with IC50 values of 16.34 ± 2.67 and 16.64 ± 1.12 μM, respectively. Compounds 3c and 3i exhibited comparable antiglycation potential with the standard, aminoguanidine. The antioxidant potential of compound 3g was found to be excellent, with an IC50 value of 28.19 ± 0.2563 μM. The binding interactions of compound 3a (binding energy = -8.833 kcal/mol) with human pancreatic α-amylase identified 3a as a potent α-amylase inhibitor. Conclusion: Enrichment of established structures with more electron-donating functionalities may assist/lead to the development of more potent antidiabetic drugs.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Future medicinal chemistry - 15(2023), 7 vom: 17. Apr., Seite 599-613 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Iqbal, Yasir [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
α-amylase |
|---|
| Anmerkungen: |
Date Completed 10.05.2023 Date Revised 11.05.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.4155/fmc-2023-0010 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM356433684 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM356433684 | ||
| 003 | DE-627 | ||
| 005 | 20231226070442.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4155/fmc-2023-0010 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1188.xml |
| 035 | |a (DE-627)NLM356433684 | ||
| 035 | |a (NLM)37140092 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Iqbal, Yasir |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a 4-Adamantyl-(2-(arylidene)hydrazinyl)thiazoles as potential antidiabetic agents |b experimental and docking studies |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 10.05.2023 | ||
| 500 | |a Date Revised 11.05.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Aim: To develop an efficient and cost-effective antidiabetic agent. Methods: A simple and convenient Hantzsch synthetic strategy was used to prepare 4-adamantyl-(2-(arylidene)hydrazinyl)thiazoles. Results: Fifteen newly established structures of 4-adamantyl-(2-(arylidene)hydrazinyl)thiazoles were tested for their α-amylase, antiglycation and antioxidant activities. Almost all tested compounds showed excellent α-amylase inhibition. Compounds 3a and 3j exhibited the highest potency, with IC50 values of 16.34 ± 2.67 and 16.64 ± 1.12 μM, respectively. Compounds 3c and 3i exhibited comparable antiglycation potential with the standard, aminoguanidine. The antioxidant potential of compound 3g was found to be excellent, with an IC50 value of 28.19 ± 0.2563 μM. The binding interactions of compound 3a (binding energy = -8.833 kcal/mol) with human pancreatic α-amylase identified 3a as a potent α-amylase inhibitor. Conclusion: Enrichment of established structures with more electron-donating functionalities may assist/lead to the development of more potent antidiabetic drugs | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a adamantane | |
| 650 | 4 | |a antiglycation | |
| 650 | 4 | |a antioxidant | |
| 650 | 4 | |a hemolysis | |
| 650 | 4 | |a molecular docking | |
| 650 | 4 | |a thiazoles | |
| 650 | 4 | |a α-amylase | |
| 650 | 7 | |a Antioxidants |2 NLM | |
| 650 | 7 | |a Thiazoles |2 NLM | |
| 650 | 7 | |a Hypoglycemic Agents |2 NLM | |
| 650 | 7 | |a alpha-Amylases |2 NLM | |
| 650 | 7 | |a EC 3.2.1.1 |2 NLM | |
| 700 | 1 | |a Akhtar, Tashfeen |e verfasserin |4 aut | |
| 700 | 1 | |a Haroon, Muhammad |e verfasserin |4 aut | |
| 700 | 1 | |a Mehmood, Hasnain |e verfasserin |4 aut | |
| 700 | 1 | |a Nizami, Tauqir |e verfasserin |4 aut | |
| 700 | 1 | |a Tahir, Ehsaan |e verfasserin |4 aut | |
| 700 | 1 | |a Ehsan, Muhammad |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Future medicinal chemistry |d 2009 |g 15(2023), 7 vom: 17. Apr., Seite 599-613 |w (DE-627)NLM194822109 |x 1756-8927 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2023 |g number:7 |g day:17 |g month:04 |g pages:599-613 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4155/fmc-2023-0010 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2023 |e 7 |b 17 |c 04 |h 599-613 | ||